Global Fellows Research Academy
Institution: Fundación Huésped
Country of work: Argentina
What is your motivation for engaging in HIV cure and remission research?
My doctoral thesis in immunomodulatory therapies during Acute HIV infection biased me through translational research. I am very interested in bringing to our site in Argentina clinical research focused in different immunological products and checkpoint blockers already approved for other indications. The availability of the Argentinean Seroconverters Group and a biological samples bank that includes live cells, serum and plasma collected from these patients since 2007 are a good assets to start this proposals together with the clinical research experience of our clinical site.
What is your current area of research?
Our center is the main clinical trial site in Argentina, we are part of the HPTN network and we will be participating in the HPTN083 trials exploring Cabotegravir vs. Truvada for PrEP. We are preparing several related projects in PrEP in our unit.
Acute HIV infection diagnosis, clinical management and treatment is an important topic for our agenda and we continue having our cohort, in collaboration with the AIDS Argentinean reference laboratory center.
New treatment strategies, such as dual therapy based on 3TC regimens (such as the GARDEL or PADDLE studies) is one important aspect of our work and we continue testing this strategy with other combinations for naïve and experienced patients.
The access, diagnosis and treatment of highly vulnerable populations, in particular transgender women, who is the most affected population in our country.